Format

Send to

Choose Destination
Expert Rev Vaccines. 2009 May;8(5):607-18. doi: 10.1586/erv.09.19.

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

Author information

1
Baxter BioScience, Biomedical Research Centre, Orth/Donau, Austria. noel_barrett@baxter.com

Abstract

The development of cell culture systems for virus propagation has led to major advances in virus vaccine development. Primary and diploid cell culture systems are now being replaced by the use of continuous cell lines (CCLs). These substrates are gaining increasing acceptance from regulatory authorities as improved screening technologies remove fears regarding their potential oncogenic properties. The Vero cell line is the most widely accepted CCL by regulatory authorities and has been used for over 30 years for the production of polio and rabies virus vaccines. The recent licensure of a Vero cell-derived live virus vaccine (ACAM2000, smallpox vaccine) has coincided with an explosion in the development of a range of new viral vaccines, ranging from live-attenuated pediatric vaccines against rotavirus infections to inactivated whole-virus vaccines against H5N1 pandemic influenza. These developments have illustrated the value of this cell culture platform in the rapid development of vaccines against a range of virus diseases.

PMID:
19397417
DOI:
10.1586/erv.09.19
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center